Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11094653 | 0.82 | MAOB (0.47) | — | |
| SCHEMBL4410547 | 0.81 | ALDH1A1 (0.54) | ALDH1A1ELANECA12CA9KMT2A | |
| SCHEMBL13459842 | 0.81 | CA12 (0.55) | ALDH1A1ELANECA12CA9KMT2A | |
| SCHEMBL9517322 | 0.80 | ALDH1A1 (0.53) | ALDH1A1ELANECA12CA9KMT2A | |
| SCHEMBL28536859 | 0.77 | LMNA (0.58) | ALDH1A1KMT2AMAPT | |
| SCHEMBL2599260 | 0.76 | ALDH1A1 (0.47) | ALDH1A1ELANECA12CA9KMT2A | |
| SCHEMBL14318320 | 0.76 | ALDH1A1 (0.47) | ALDH1A1ELANECA12CA9KMT2A | |
| SCHEMBL12869027 | 0.76 | ALDH1A1 (0.56) | ALDH1A1ELANECA12CA9KMT2A | |
| SCHEMBL2599263 | 0.76 | ALDH1A1 (0.47) | ALDH1A1ELANECA12CA9KMT2A | |
| SCHEMBL17280822 | 0.75 | ALDH1A1 (0.64) | ALDH1A1ELANECA12CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-08-08 | — | — | US | disclosed |
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-08-08 | — | — | US | disclosed |
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-08-08 | — | — | US | disclosed |
| WO-2012058133-A1 | ISOINDOLINONE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203756-A1 | ISOINDOLINE PDE10 INHIBITORS | PDE12, PDE10A, PDE4A | ALDH1A1 620/4885ELANE 1636/4885CA12 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.